"Shuganning injection post-marketing clinical safety re-evaluation research program demonstration meeting" was successfully held in Guiyang.

On March 27, the program demonstration meeting of "clinical safety re evaluation research of Shuganning injection after marketing" undertaken by the First Affiliated Hospital of Henan University of traditional Chinese medicine was held in Guiyang.

The meeting was presided over by Zhu Mingjun, President of the First Affiliated Hospital of Henan University of Traditional Chinese Medicine. Relevant experts participating in this demonstration meeting include Professor Wang Baohe from the Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Professor Guo Peng from Xiyuan Hospital of Chinese Academy of Medical Sciences, Professor Cheng Mingliang from the Affiliated Hospital of Guizhou Medical University, Dr. Liu Mei from You'an Hospital of Capital Medical University, and PLA General Dr. Liu Yan from the Fifth Medical Center of the Hospital, etc. Professor Li Xuelin, Associate Professor Li Chunxiao, Dr. Ling Xiao, Chairman Yuan Jun of Shanghai Yongzheng Pharmaceutical Technology Co., Ltd., Chairman Xiong Yigang and General Manager Zhao Yun of Guizhou Ruihe Pharmaceutical Co., Ltd. attended the meeting.

At the scheme demonstration meeting, general manager Zhao yun made a welcome speech, and the research and development department reported in detail the prescription source, production management, quality control, pharmacological effect, clinical research and other product information of shuganning injection to the demonstration experts.

On behalf of the team, Dr. Ling Xiao from the research group of the First Affiliated Hospital of Henan University of Traditional Chinese Medicine reported in detail the "Research Plan for Clinical Safety Re-evaluation of Shuganning Injection after Marketing". At the same time, Associate Professor Li Chunxiao made a report on "Research on Comprehensive Clinical Safety Evaluation of Shuganning Injection after Marketing". The participating experts had a heated discussion on the research plan and put forward valuable opinions and suggestions.

This demonstration meeting played a great role in further clarifying the research objectives and improving the scheme.

Finally, the company's chairman Xiong Yigang on the development of Shuganning injection clinical safety centralized monitoring, drug safety risk assessment put forward a few hopes, product marketing clinical safety research is to fulfill the pharmaceutical enterprises to the patient's drug safety of the main responsibility, to ensure the public drug safety of specific measures. It is hoped that all parties will earnestly organize, unite and cooperate to ensure the smooth completion of the project.